End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12.75 CNY | -2.52% | -2.97% | -14.94% |
Apr. 24 | HitGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Feb. 23 | HitGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 100.66 times its estimated earnings per share for the ongoing year.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-14.94% | 704M | - | ||
+9.58% | 115B | B+ | ||
+12.41% | 107B | B+ | ||
-3.44% | 21.6B | B | ||
-12.38% | 22.31B | B+ | ||
-6.87% | 19.19B | A- | ||
-3.35% | 18.23B | B | ||
-38.57% | 17.62B | A- | ||
+7.51% | 14.26B | C+ | ||
+35.67% | 12.37B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 688222 Stock
- Ratings HitGen Inc.